Entain announces a recommended cash offer to the shareholders of Enlabs AB
USA - English
Dela den här artikeln
This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled Important information at the end of this announcement and in the offer document which will be published shortly before the commencement of the acceptance period under the Offer. Shareholders in the United States should also refer to the section titled Special notice to shareholders in the United States at the end of this announceme
African startup aims to become the âSpotify of Africaâ
By Chad Williams
Share
Cape Town - An African startup says it wants to become the continentsâ largest music streaming service, and afford artists the opportunity to garner streaming revenue and royalties.
According to a CNN report Mdundo, a Kenya-based platform set up in 2013 by Danish expatriate Martin Nielsen, provides access to the continent s favourite music to more than six million monthly active users.
The service has over 20 million monthly downloads and streams via its website and application. It is available throughout the continent, although until recently it focused mainly on East Africa.
Nexstim Oyj: Nexstim Has Received Three New NBS System Orders
Nexstim Has Received Three New NBS System Orders
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received three new NBS system orders in December.
One purchase order came from a new neurosurgical customer in Spain. Two other orders came from existing Nexstim system users in Finland and in the United States. Those two orders are for NBS System upgrades meaning that an NBS System with the latest SmartFocus nTMS features will replace the hospital s older NBS system.
Nexstim NBS systems with SmartFocus nTMS are mainly used for neurosurgical diagnostics to provide information on tumour s or on other lesion s location in relation to the essential functions and their connections in the patient s brain. In addition, NBS Systems are used in research and in Europe the systems can also be used for depression and chronic, neuropathic pain therapy.
Share:
Nexstim Has Received Three New NBS System Orders
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received three new NBS system orders in December.
One purchase order came from a new neurosurgical customer in Spain. Two other orders came from existing Nexstim system users in Finland and in the United States. Those two orders are for NBS System upgrades meaning that an NBS System with the latest SmartFocus® nTMS features will replace the hospital s older NBS system.
Nexstim NBS systems with SmartFocus® nTMS are mainly used for neurosurgical diagnostics to provide information on tumour s or on other lesion s location in relation to the essential functions and their connections in the patient s brain. In addition, NBS Systems are used in research and in Europe the systems can also be used for depression and chronic, neuropathic pain therapy.
First dosing of nanoformed drug successfully accomplished
Nanoform
Press Release
First dosing of nanoformed drug successfully accomplished
Helsinki, Finland – Nanoform Finland Plc (“
Nanoform”), an innovative nanoparticle medicine enabling company, today announced that the first full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ facilities in Nottingham, UK, been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate using Nanoform’s proprietary CESS
® technology. Results are expected before the end of Q2/2021.
Nanoform has now achieved all its near-term business targets for 2020 and 2021 announced in relation to the IPO. New near-term business targets, in addition to the previously (November 27th) announced “First Biologics PoC project in 2021”, will be communicated in the coming months.